Back to top

Is ASSERTIO THERAPEUTICS, INC (ASRT) Stock Outpacing Its Medical Peers This Year?

Read MoreHide Full Article

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. ASSERTIO THERAPEUTICS, INC (ASRT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of ASRT and the rest of the Medical group's stocks.

ASSERTIO THERAPEUTICS, INC is one of 844 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ASRT is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for ASRT's full-year earnings has moved 18.58% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Our latest available data shows that ASRT has returned about 18.56% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 1.38% on a year-to-date basis. This shows that ASSERTIO THERAPEUTICS, INC is outperforming its peers so far this year.

To break things down more, ASRT belongs to the Medical - Drugs industry, a group that includes 174 individual companies and currently sits at #97 in the Zacks Industry Rank. On average, this group has gained an average of 6% so far this year, meaning that ASRT is performing better in terms of year-to-date returns.

Going forward, investors interested in Medical stocks should continue to pay close attention to ASRT as it looks to continue its solid performance.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


ASSERTIO THERAPEUTICS, INC (ASRT) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in